BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 33590326)

  • 1. Immunotherapeutic advances in gastric cancer.
    Yoneda A; Kuroki T; Eguchi S
    Surg Today; 2021 Nov; 51(11):1727-1735. PubMed ID: 33590326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
    Zeng Z; Yang B; Liao Z
    Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized Immuno-Oncology.
    Jain KK
    Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in advanced gastric cancer, is it the future?
    Coutzac C; Pernot S; Chaput N; Zaanan A
    Crit Rev Oncol Hematol; 2019 Jan; 133():25-32. PubMed ID: 30661655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frontiers in cancer immunotherapy-a symposium report.
    Cable J; Greenbaum B; Pe'er D; Bollard CM; Bruni S; Griffin ME; Allison JP; Wu CJ; Subudhi SK; Mardis ER; Brentjens R; Sosman JA; Cemerski S; Zavitsanou AM; Proia T; Egeblad M; Nolan G; Goswami S; Spranger S; Mackall CL
    Ann N Y Acad Sci; 2021 Apr; 1489(1):30-47. PubMed ID: 33184911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunotherapy revolution in genitourinary malignancies.
    U Gandhy S; Madan RA; Aragon-Ching JB
    Immunotherapy; 2020 Aug; 12(11):819-831. PubMed ID: 32594815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Progression of immunotherapy in gastric cancer].
    Wei X; Xu R
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Feb; 19(2):225-32. PubMed ID: 26831889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in Advanced Lung Cancer.
    Huang J; Reckamp KL
    Oncology (Williston Park); 2020 Jul; 34(7):272-279. PubMed ID: 32674216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in Advanced Non-Small Cell Lung Cancer.
    Huang J; Reckamp KL
    Semin Respir Crit Care Med; 2020 Jun; 41(3):400-408. PubMed ID: 32450594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A; Burns TF
    J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of gastric cancer: Past, future perspective and challenges.
    Xie J; Fu L; Jin L
    Pathol Res Pract; 2021 Feb; 218():153322. PubMed ID: 33422778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
    Cavalcante L; Chowdhary A; Sosman JA; Chandra S
    Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic strategies for gastric cancer targeting immune cells: Future directions.
    Zhao Y; Bai Y; Shen M; Li Y
    Front Immunol; 2022; 13():992762. PubMed ID: 36225938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for hepatocellular carcinoma.
    Zongyi Y; Xiaowu L
    Cancer Lett; 2020 Feb; 470():8-17. PubMed ID: 31811905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
    Cheng AL; Hsu C; Chan SL; Choo SP; Kudo M
    J Hepatol; 2020 Feb; 72(2):307-319. PubMed ID: 31954494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).
    Kong X; Lu P; Liu C; Guo Y; Yang Y; Peng Y; Wang F; Bo Z; Dou X; Shi H; Meng J
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Challenges of Immune Checkpoint Inhibitors.
    de Miguel M; Calvo E
    Cancer Cell; 2020 Sep; 38(3):326-333. PubMed ID: 32750319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.